干旱区生态环境知识资源中心(Arid): DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer

Arid

DOI	10.3389/fcell.2021.760369
	DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer
	Ye, Fangdie; Liang, Yingchun; Hu, Jimeng; Hu, Yun; Liu, Yufei; Cheng, Zhang; Ou, Yuxi; Xu, Chenyang; Jiang, Haowen
通讯作者	Xu, CY ; Jiang, HW (corresponding author), Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China. ; Xu, CY ; Jiang, HW (corresponding author), Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China. ; Jiang, HW (corresponding author), Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Fudan, Peoples R China.
来源期刊	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
ISSN	2296-634X
出版年	2021
卷号	9
英文摘要	Background: Considering the heterogeneity and complexity of epigenetic regulation in bladder cancer, the underlying mechanisms of global DNA methylation modification in the immune microenvironment must be investigated to predict the prognosis outcomes and clinical response to immunotherapy.Methods: We systematically assessed the DNA methylation modes of 985 integrated bladder cancer samples with the unsupervised clustering algorithm. Subsequently, these DNA methylation modes were analyzed for their correlations with features of the immune microenvironment. The principal analysis algorithm was performed to calculate the DMRscores of each samples for qualification analysis.Findings: Three DNA methylation modes were revealed among 985 bladder cancer samples, and these modes are related to diverse clinical outcomes and several immune microenvironment phenotypes, e.g., immune-desert, immune-inflamed, and immune-excluded ones. Then patients were classified into high- and low-DMRscore subgroups according to the DMRscore, which was calculated based on the expression of DNA methylation related genes (DMRGs). Patients with the low-DMRscore subgroup presented a prominent survival advantage that was significantly correlated to the immune-inflamed phenotype. Further analysis revealed that patients with low DMRscores exhibited less TP53 wild mutation, lower cancer stage and molecular subtypes were mainly papillary subtypes. In addition, an independent immunotherapy cohort confirmed that DMRscore could serve as a signature to predict prognosis outcomes and immune responses.Conclusion: Global DNA methylation modes can be used to predict the immunophenotypes, aggressiveness, and immune responses of bladder cancer. DNA methylation status assessments will strengthen our insights into the features of the immune microenvironment and promote the development of more effective treatment strategies.
英文关键词	bladder cancer DNA methylation regulators immunotherapy prognostic model tumor microenvironment
类型	Article
语种	英语
开放获取类型	Green Accepted, gold
收录类别	SCI-E
WOS记录号	WOS:000731015900001
WOS关键词	BLOCKADE
WOS类目	Cell Biology ; Developmental Biology
WOS研究方向	Cell Biology ; Developmental Biology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/374108
作者单位	[Ye, Fangdie; Liang, Yingchun; Hu, Jimeng; Hu, Yun; Liu, Yufei; Cheng, Zhang; Ou, Yuxi; Xu, Chenyang; Jiang, Haowen] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China; [Ye, Fangdie; Liang, Yingchun; Hu, Jimeng; Hu, Yun; Liu, Yufei; Cheng, Zhang; Ou, Yuxi; Xu, Chenyang; Jiang, Haowen] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China; [Jiang, Haowen] Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Fudan, Peoples R China
推荐引用方式 GB/T 7714	Ye, Fangdie,Liang, Yingchun,Hu, Jimeng,et al. DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer[J],2021,9.
APA	Ye, Fangdie.,Liang, Yingchun.,Hu, Jimeng.,Hu, Yun.,Liu, Yufei.,...&Jiang, Haowen.(2021).DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer.FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,9.
MLA	Ye, Fangdie,et al."DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer".FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 9(2021).